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Abstract
Randomized Controlled Trials (RCTs) are
the gold standard for comparing the effec-
tiveness of a new treatment to the current
one (the control). Most RCTs allocate the
patients to the treatment group and the con-
trol group by uniform randomization. We
show that this procedure can be highly sub-
optimal (in terms of learning) if – as is often
the case – patients can be recruited in co-
horts (rather than all at once), the effects
on each cohort can be observed before re-
cruiting the next cohort, and the effects are
heterogeneous across identifiable subgroups
of patients. We formulate the patient al-
location problem as a finite stage Markov
Decision Process in which the objective is
to minimize a given weighted combination
of type-I and type-II errors. Because find-
ing the exact solution to this Markov Deci-
sion Process is computationally intractable,
we propose an algorithm – Knowledge Gradi-
ent for Randomized Controlled Trials (RCT-
KG) – that yields an approximate solution.
We illustrate our algorithm on a synthetic
dataset with Bernoulli outcomes and com-
pare it with uniform randomization. For a
given size of trial our method achieves sig-
nificant reduction in error, and to achieve a
prescribed level of confidence (in identifying
whether the treatment is superior to the con-
trol), our method requires many fewer pa-
tients. Our approach uses what has been
learned from the effects on previous cohorts
to recruit patients to subgroups and allocate
patients (to treatment/control) within sub-
groups in a way that promotes more efficient
learning.
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1 Introduction
Randomized Controlled Trials (RCTs) are the gold
standard for evaluating new treatments. Phase I tri-
als are used to evaluate safety and dosage, Phase II
trials are used to provide some evidence of efficacy,
and Phase III trials (which are the subject of this pa-
per) are used to evaluate the effectiveness of the new
treatment in comparison to the current one. A typi-
cal question that a Phase III RCT is intended to an-
swer is “In population W is drug A at daily dose X
more efficacious in improving Z by Q amount over
a period of time T than drug B at daily dose Y?”
[Friedman et al. (1998)].
RCTs are useful because they create a treatment group
and a control group that are as similar as possi-
ble except for the treatment used. Most RCTs re-
cruit patients from a prescribed target population and
uniformly randomly assign the patients to treatment
groups using repeated uniform randomization (per-
haps adjusted to deal with chance imbalances). This
approach is optimal if all patients are recruited at
once or if the outcomes for previous patients can-
not be observed when recruiting new patients or if
the patient population is (or is thought to be) ho-
mogeneous. However, in many circumstances, pa-
tients are (or can be) recruited in cohorts, the out-
comes for patients in previous cohorts can be observed
when recruiting a new cohort, and the population con-
tains identifiable subgroups for which differences in
effects might be expected. (For example, different
effects of treatment might be expected for patients
with different genetic mutations [Moss et-al. (2015)];
see [He´bert et al.(1999)] and Table 1 for additional ex-
amples.) In such situations, the information learned
from previous cohorts can be used in recruiting and al-
locating patients in the new cohort: the optimal policy
should not necessarily recruit the same number of pa-
tients to each identifiable subgroup or allocate equal
numbers of patients within a subgroup to the treat-
ment and the control. We illustrate this point in the
Experiments.
Our goal in this paper is to develop a procedure that
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prescribes two things: (i) the number of patients in
each cohort to recruit from each subgroup, (ii) the al-
location of these patients to treatment or control in
order to minimize the error (type-I or type-II or a
given convex combination) in identifying the patient
subgroups for which the treatment is more/less effec-
tive than the control. Our work differs from recent
work on Bayesian clinical trials [Berry et al. (2006)]
in which the the information obtained from the pre-
vious cohorts are used only for treatment allocation;
in our work, the information from previous cohorts
is used both for patient recruitment and for alloca-
tion to treatment or control. As an example, consider
the RCT setting in [Barker et al. (2009)] for neoadju-
vant chemotherapy in which two subgroups are identi-
fied based on the hormone receptor status, human epi-
dermal growth factor receptor 2 (HER2) status, and
MammaPrint11,12 status. If our procedure were to
be used in this actual trial to recruit 100 patients in
each cohort, the initial cohort would consist of 50 pa-
tients from each subgroup and would allocate them
uniformly to treatment/control. However, in the sec-
ond and succeeding cohorts, we would use the observed
outcomes from earlier cohorts to recruit more patients
from the subgroup in which uncertainty about treat-
ment efficacy was larger and, within each subgroup,
we would allocate more patients to whichever of treat-
ment/control had displayed larger variance.
Our first contribution is to formalize the learning prob-
lem as a finite stage Markov Decision Problem (MDP)
in which the designer recruits N patients over K
steps and observes the outcomes of step k − 1 be-
fore taking step k. However, because the action and
state spaces of this MDP are very large, solving this
MDP by dynamic programming is computationally in-
tractable. We therefore propose a computationally
tractable greedy algorithm Knowledge Gradient for
Randomized Controlled Trials (RCT-KG) that yields
an approximate solution. We illustrate the effective-
ness of our RCT-KG algorithm in a set of experiments
using synthetic data in which outcomes are drawn
from a Bernoulli distribution with unknown probabil-
ities. In particular, we show that, keeping the sizes
of the trial and of the cohorts fixed, RCT-KG yields
significantly smaller expected error; conversely, in or-
der to achieve a given level of confidence in identify-
ing whether the treatment is better than the control,
RCT-KG requires many fewer patients/cohorts.
Our approach makes a number of assumptions. The
first is that patients can be recruited in cohorts, and
not all at once. The second is that the outcomes for pa-
tients in each cohort are realized and can be observed
before recruiting and allocating patients for the suc-
ceeding cohort. The third is that subgroups are iden-
tified in advance. The fourth is that, for each cohort
(after the first), the number of patients recruited in
each subgroup and the allocation of patients (to treat-
ment or to control) within each subgroup can be cho-
sen to depend on the observations made from previous
cohorts. These assumptions are strong and certainly
are not satisfied for all RCTs, but they are satisfied
for some RCTs, and for those our approach offers very
significant improvements over previous approaches to
the speed and accuracy of learning.
It is important to understand that these assumptions
do not imply that our approach is entirely unblinded.
In each cohort, the assignment of patients within each
subgroup to treatment/control is completely blind to
both patients and clinicians; it is only after the as-
signment is made and the outcome is realized that the
clinicians learn which patients received the treatment
and which received the control. Moreover, In each co-
hort, the assignment of patients within each subgroup
to treatment/control is completely random, although
the particular randomization used for a particular sub-
group in a particular cohort depends on the outcomes
that have been observed for previous cohorts.
2 Related Work
The most commonly used procedure to allocate pa-
tients into treatment and control groups is “repeated
fair coin-tossing” (uniform randomization). One po-
tential drawback to this approach is the possibil-
ity of unbalanced group sizes when the set of pa-
tients (or the set of patients in an identified sub-
group) is small [Friedman et al. (1998)]. Hence, inves-
tigators often follow a restricted randomization pro-
cedure for small RCTs, such as blocked randomiza-
tion [Lachin et al. (1988)] or adaptive bias-coin ran-
domization [Schulz and Grimes (2002)]. These proce-
dures have the effect of assigning more patients to
treatment/control groups to prevent an imbalance be-
tween the groups. An alternative, but less frequently
used procedure is covariate-adaptive randomization
in which patients are assigned to treatment groups
to minimize covariate imbalance [Moher et al. (2012)].
These approaches are efficient when patients are re-
cruited at one time or the outcomes of previous
cohorts are not observed . However, as we have
noted and can be seen in Table 1, it is often the
case that patients are recruited sequentially in co-
horts and the outcomes of previous cohorts can be
observed before recruiting the next cohort. There
is a substantial literature concerning such settings
[Lewis and Bessen (1990), Whitehead (1997)], but it
focuses on the decision of whether to terminate the
trial, rather than how to allocate the next cohort of
patients to the treatment or control groups, which is
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Study Size Treatment Primary Outcome Result
[Hacke et al. (1995)] 620 rt-PA (alteplase) Barthel Index (BI) at 90
days
Treatment is effective in improving the outcome
in a defined subgroup of stroke patients.
[He´bert et al.(1999)] 838 Red cell transfusion 30 days mortality effective among the patients with Apache 2 score
less than equal to 20 and age less than 55.
[Hacke et al. (2008)] 821 Intravenous thromboly-
sis with alteplase
disability at 90 days As compared with placebo, intravenous alteplase
improved clinical outcomes significantly.
[Moss et-al. (2015)] 69 Ivacaftor ppFEV1 in week 24 Ivacaftor significantly improves lung function in
adult patients with R117H-CFTR.
Table 1: RCT Examples in the Literature
the focus of our paper.
Response adaptive randomization uses information
about previous cohorts to allocate patients in suc-
ceeding cohorts: the probability of being assigned
to a treatment group is increased if responses
of prior patients in that particular group has favor-
able [Hu and Rosenberger (2006),Berry et al. (2006)].
However, the goal of the most of these approaches
is to improve the benefit to the patients in the trial
rather than to learn more about the comparison
between the treatment and the control. Multi-Armed
Bandits (MABs) constitute a general mathematical
decision framework for resource (patient) allocation
with the objective of maximizing the cumulative
outcomes (patient benefits) [Auer et al. (2002),
Gittins et al. (2011), Agrawal and Goyal (2012)].
However, [Villar et al. (2015)] shows that although
MABs achieve greater patient benefit, they suffer
from poor learning performance because they allocate
most of the patients to favorable actions (treatments).
Hence, [Villar et al. (2015)] proposes a variation on
MAB algorithms that allocates patients to control
action at times to maintain patient benefit while mit-
igating the poor learning performance. Some of the
existing work on Bayesian RCTs [Berry et al. (2006)]
does use the information from previous cohorts to
allocate patients in order to improve the learning
performance. The work closest to ours may be ??
which specifically addresses the special case of a trial
with two identified subgroups. However the only
adaptation considered is to entirely cease recruiting
patients into one of the subgroups, not to change the
number of patients recruited into each subgroup. Our
paper prescribes a principled algorithm to improve the
learning performance that adjusts both the number
of patients recruited into each subgroup and the
proportion of patients allocated to treatment/control
within each subgroup.
Another line of literature relevant to ours is family
of policies known as Optimal Computing Budget Al-
location (OCBA) [Chen (1995), Chen et al. (2003)].
These policies are derived as an optimization prob-
lem to maximize the probability of later identify-
ing the best alternatives by choosing the measure-
ments. The approach in these policies is by approxi-
mating the objective function with lower and upper
bounds. In this paper, we provide a Bayesian ap-
proach to RCT design and model the problem as a
finite stage MDP. The optimal patient allocation pol-
icy can be obtained by solving the Dynamic Program-
ming (DP); for the case of discounting, the Gittins
Index [Gittins et al. (2011),Whittle (1980)] provides
an (optimal) closed form solution to the MDP. How-
ever, both of these approaches are computationally in-
tractable for problems as large as typical RCTs.
Knowledge Gradient (KG) policies provide an ap-
proximate, greedy approach to the MDP. However,
in our setting, the action space for the MDP, which
contains all possible allocation choices, is very large
and hence KG policies are again not computation-
ally tractable. (Morever, KG policies typically as-
sume multivariate normal priors for the measure-
ments [Frazier et al. (2008), Frazier et al. (2009)].).
[Chen et al. (2013), Chen et al. (2015)] proposes a
variation of KG policies that they deemed Opt-KG and
that selects the action that may generate maximum
possible reduction in the errors. In our setting, their
approach would require that patients be recruited one
at a time and that the outcome of the action (treat-
ment or control) chosen for each patient from each
subgroup be observable before the next patient is re-
cruited. Those requirements are not appropriate for
our setting, in which we observe only a (noisy) signal
about the true outcome of the selected treatment and
we recruit patients in cohorts. not one at a time. (It
would typically be completely impractical to allocate
patients one at a time: for any realistic time to obser-
vation and total number of patients, doing so would re-
sult in a clinical trial that would last for many years.)
Moreover, our approach allow for a much broader class
of outcome distributions (exponential families, which
includes Bernoulli distributions and many others) and
we allocate all patients in a cohort at each stage. Our
RCT-KG algorithm might be viewed as generalizing
Opt-KG in all of the aspects mentioned.
3 A Statistical Model for a
Randomized Clinical Trial
Our statistical model for a RCT has four components:
the patient population, the given patient subgroups,
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the treatments and the treatment outcomes. Write
W for the patient population and X for a prescribed
partition of W into patient subgroups. Write Y =
{0, 1} for the action space; 0 represents the control
action and 1 represents the treatment action. Let Z
be the outcome space; without much loss we assume
Z ⊂ R with minimum zmin and maximum zmax. (Z
might be continuous or discrete.)
We wish to allocate a total of N patients in K
steps/cohorts over a total time T in order to identify
the more efficacious treatment for each subgroup. As
discussed in the Introduction, we make the following
assumptions:
1. Patients can be be recruited in cohorts.
2. The outcomes for patients in each cohort are re-
alized and can be observed before recruiting and
allocating patients for the succeeding cohort.
3. Subgroups can be identified in advance.
4. For each cohort after the first, the number of pa-
tients recruited in each subgroup and the alloca-
tion within each subgroup can be chosen as a func-
tion of the observations from previous cohorts.
In addition, we make one technical assumption:
5. The outcome distribution belongs to the exponen-
tial family.
In the next subsection, we give a brief description of
the exponential family of distributions and Jeffrey’s
prior on their parameters.
3.1 Exponential Families and Jeffrey’s Prior
Let Θ be a parameter space. Fix functions G : Z →
R
d and h : Z → R. The d-dimensional parame-
ter exponential family with sufficient statistic G and
parametrization θ, relative to h, is the family of dis-
tributions defined by the following densities:
p(z|θ) = Φ(θ)h(z) exp (θ·G(z))
where Φ(θ) is uniquely determined by the requirement
that p(·|θ) is a probability density; hence∫ ∞
−∞
p(z|θ)d z = 1
Φ(θ) =
(∫ ∞
−∞
h(z) exp(θ·G(z))d (z)
)−1
An alternative expression is:
p(z|θ) = h(z) exp (θ·G(z)− F (θ))
where F (θ) = − logΦ(θ). Write µ for the expecta-
tion: µ(θ) = EZ|θ [Z]. Different choices of the various
ingredients lead to a wide variety of different probabil-
ity densities; for example choosing G(z) = z, h(z) =
1, θ = ln q1−q generates a Bernoulli distribution. Other
choices lead to Poisson, exponential and Gaussian dis-
tributions.
In this paper, we want a Bayesian “non-informative”
prior that is invariant under re-parametrization of the
parameter space. To be specific, we use Jeffrey’s prior,
which is proportional to the square root of the Fisher
information I(θ). In the case of the exponential family,
the Fisher information is the second derivative of the
normalization function, i.e., I(θ) =
√∣∣F ′′(θ)∣∣. Under
Jeffrey’s prior, the posterior on the parameter θ after
n observations is given by
p(θ|z1, . . . , zn) ∝
√∣∣F ′′(θ)∣∣ exp
(
n∑
i=1
θ·G(zi)− nF (θ)
)
Given n outcomes (z1, z2, . . . , zn), we can summarize
the information needed for the posterior distribution
by s = [s0, s1] = [
∑n
i=1G(zi), n]. The posterior is then
proportional to
√∣∣F ′′(θ)∣∣ exp (θ·s0 − s1F (θ)).
Given a subgroup x ∈ X and a treatment y ∈ Y Let
θx,y be the true parameter for subgroup x and treat-
ment y. (Of course θx,y is not known.) The result of
treatment y on a patient in subgroup x is referred to
as the treatment outcome and is assumed to be drawn
according to the exponential family distribution, i.e.,
Z ∼ p(·|θx,y). Write µ(θx,y) for the true expected
outcome of the treatment y on subgroup x and de-
fine the treatment effect for the parameters θ0, θ1 as
E(θ0, θ1) = µ(θ1)−µ(θ0); the treatment effect on sub-
group x is E(θ0,x, θ1,x).
3.2 Treatment Effectiveness
Given a threshold τ ≥ 0 (set be the designer), we
define
ν(x) =
{
1 if
E(θx,0,θx,1)
µ(θx,0)
≥ τ
0 if otherwise
so ν(x) = 1 if the treatment is sufficiently better than
the control, in which case we say the treatment is effec-
tive. (For example, see [Farrar et al. (2000)], in which
the goal is to identify whether reduction in pain by the
treatment with respect to control is more than 33%.)
We define the positive set H+ = {x ∈ X : ν(x) = 1}
to be the set of subgroups for which the treatment is
effective and the negative set H− = X \H− to be the
complementary set of subgroups for which the treat-
ment is ineffective.
Given the dataset, any algorithm can only produce a
set of subgroups in which treatment is estimated to be
effective; write H+est for this set of subgroups and H
−
est
for the complementary set of subgroups. A type-I error
occurs if a subgroup x ∈ H+ is in H−est (i.e. treatment
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is actually effective but is estimated to be ineffective);
a type-II error occurs if a subgroup x ∈ H− is in H+
(i.e. treatment is actually ineffective but is estimated
to be effective). For a given estimated set H+est, the
magnitudes of type-I and type-II errors are
eK1 =
∑
x∈X
1
(
x ∈ H+
)
1
(
x ∈ H−est
)
eK2 =
∑
x∈X
1
(
x ∈ H−
)
1
(
x ∈ H+est
)
Given λ ∈ [0, 1] the total error is:
eK = λeK1 + (1− λ)e
K
2
where λ is a parameter that is selected by the designer
based on the designer’s view of the importance of type-
I and type-II errors. (We use the superscript K to
indicate that we are computing errors after K cohorts
have been recruited.)
4 Design of a RCT as a Markov
Decision Problem
In this subsection, we model the RCT design prob-
lem as a finite step non-discounted MDP. A finite step
MDP consists of number of steps, a state space, an ac-
tion space, transition dynamics and a reward function.
We need to define all the components of the MDP.
We are given a budget of N patients to be re-
cruited in K steps. At time step k, the designer
decides to recruit Mk patients; of these uk(x, y) are
from subgroup x and are assigned to treatment y, so∑
x∈X
∑
y∈Y uk(x, y) = Mk. Having made a decision
Uk = {uk(x, y)} in step k, the designer observes the
outcomes Wk = {Wk(x, y) =
∑uk(x,y)
j=1 G(Zj) : Zj ∼
P(·|θx,y)}.
Write M¯k−1 =
∑k−1
ℓ=0 Mℓ for the number of patients
recruited through step k − 1. We define a filtration
(Fk)
K
k=0 by setting F
k to be the sigma-algebra gen-
erated by the decisions and observations through step
k − 1: {U0,W 0, U1,W 1 . . . , Uk−1,W k−1}. We write
Ek [·] = E
[
·|Fk
]
and Vark [·] = Var
[
·|Fk
]
. Recruit-
ment and allocation decisions are restricted to be Fk-
measurable so that decisions to be made at each step
depends only on information available from previous
steps.
The state space for the MDP is the space of all possible
distributions under consideration for {θx,y}. Let S
k
denote the 2X × (d + 1) state matrix that contains
the hyper-parameters of posterior distribution of the
outcomes for both treatment and control actions for
all (x, y) ∈ X × Y in the kth step. Define Sk to be
the all possible states at the kth step, that is, Sk =
{
Sk =
[
skx,y
]
: skx,y =
[
skx,y,0, sx,y,1
]}
where skx,y,0
is the d-dimensional cumulative sufficient statistic and
sx,y,1 is the number of samples from subgroup x with
treatment action y.
The action space at step k is the set of all possible pairs
of (Mk, Uk) withMk ≤ N−M¯k−1 and
∑
x,y uk(x, y) =
Mk. Taking an action ak = (Mk, Uk) means recruiting
Mk patients in total, of whom uk(x, y) will be from
subgroup x and assigned to treatment y. Fix the deci-
sion stage as k. When the designer selects one of the
actions, we use Bayes rule to update the distribution of
θx,y conditioned on F
k based on outcome observations
of Wk, obtaining a posterior distribution conditioned
on Fk+1. Thus, our posterior distribution for θx,y is
proportional to
√∣∣F ′′(θ)∣∣ exp (θ·skx,y,0 − F (θ)skx,y,1).
The parameters of the posterior distribution can be
written as a function of sk and Wk. Define S
k+1 =
T (sk, ak,Wk) to be the transition function given ob-
served treatment outcome Wk and P(S
k+1|Sk, ak) to
be the posterior state transition probabilities condi-
tioned on the information available at step k. Having
taken an allocation action ak = (Mk, Uk), the state
transition probabilities are: Sk+1 = sk +
[
W k, Uk
]
with posterior predictive probability P(W |sk).
For a state s = (s0, s1), the action space is the set
of pairs of (m,u) with m less than or equal to the
remaining patient budget, and elements in u summing
up to m. Denote this set as A(s).
Given the state vector s, write Px(s) for the posterior
probability that the treatment is effective, conditional
on θx,0 and θx,1 being drawn according to the posterior
distributions. Formally,
Px(s) = P
(
E(θ0, θ1)
µ(θ0)
≥ τ
∣∣∣∣θ0∼Pθ|sx,0,0,sx,0,1θ1∼Pθ|sx,1,0,sx,1,1
)
.
We can now compute estimated positive and negative
sets, H+est, H
−
est. If x ∈ H
−
est (i.e. the treatment is
estimated to be ineffective for the subgroup x) then
the probability that x ∈ H+ (i.e. the treatment is
actually effective) is Px(s). Similarly, if x ∈ H
+
est then
the probability that x ∈ H− is 1−Px(s). Hence, given
H+est, H
−
est the posterior expected total error is:∑
x∈X
λPx(s)1(x ∈ H
−
est)
+ (1− λ)(1 − Px(s))1(x ∈ H
+
est) (1)
The following proposition identifies the set that mini-
mizes this posterior expected total error.
Proposition 1. Given the terminal state s, the set
that minimizes this posterior expected total error is
H+est = {x ∈ X : Px(s) ≥ 1− λ}.
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Proof. Fix a particular subgroup x. If the subgroup
x is in the estimated positive set, then total expected
error for subgroup x is given by λPx(s). Similarly, if
the subgroup x is in the estimated negative set, then
total expected error for subgroup x is given by (1 −
λ)(1 − Px(s)). When Px(s) ≥ 1 − λ, it holds that
λPx(s) ≥ (1 − λ)(1 − Px(s)). In that case, x ∈ H
+
est
minimizes the total expected posterior error.
Now define g by
g(x;λ) = λ(1− x)1(x ≥ 1− λ) + (1− λ)x1(x < 1− λ).
Then, the posterior expected total error can be written
as eK =
∑
x∈X g
(
Px(s
K);λ
)
. We’ll omit using λ in
the rest of the paper for notational brevity. We define
the reward function R : S × A → R as the decrease
in the posterior expected total error that results from
taking a particular action in state s; i.e.
R(s, a) =
∑
x∈X
E
[
g
(
Px(s
k)
)
− g
(
Px(s
k+1)
) ∣∣sk = s, ak = a]
where the expectation is taken with respect to the out-
come distributions of the treatment and control ac-
tions given the state vector s. A policy is a mapping
pi : S → A from the state space to the action space,
prescribing the number of patients to recruit from each
subgroup and how to assign them to treatment groups.
The value function of a policy pi beginning from state
s0 is
V π(s0) = B(s0)−
∑
x∈X
E
π
[
g
(
Px(s
k);λ
)]
=
K∑
k=0
E
π
[
R(Sk, Ak)
]
(2)
where B(s0) =
∑
x∈X g
(
Px(s
0);λ
)
and the expec-
tation is taken with respect to the policy pi. Our
learning problem is the K-stage MDP with tu-
ple: {K, {Sk}, {A(s)}, T (sk, ak,Wk), R(s
k, ak)} and
our goal is to solve the following optimization prob-
lem:
maximizeπ
K∑
k=1
E
π
[
R(Sk, pi(Sk))
]
subject to pi(Sk) ∈ A(Sk) for all k
In the next subsection, we propose a Dynamic Pro-
gramming (DP) approach for solving the K-stage
MDP defined above.
4.1 Dynamic Programming (DP) solution
In the dynamic programming approach, the value
function is defined as the optimal value function given
a particular state Sk at a particular stage k, and is de-
termined recursively through Bellman’s equation. If
the value function can be computed efficiently, the op-
timal policy can also be computed from it. The op-
timal value function at the terminal stage K − 1 (the
stage in which the last patient is recruited) is given by:
V K−1(s) = max
a∈A(s)
R(s, a)
The dynamic programing principle tells us that the
loss function at other indices 0 ≤ k < K − 1 is given
recursively by
Qk(s, a) = Ek
[
V k(T (s, a,W ))
]
,
V k(s) = maxa∈A(s)Q
k(s, a)
where the expectation is taken with respect to the dis-
tribution of the cumulative treatment outcomes W .
The dynamic programming principle tells us that any
policy that satisfies the following is optimal: A∗k =
argmaxa∈A(Sk) = Q
k(Sk, a).
However, it is computationally intractable to solve the
DP because the state space contains all possible dis-
tributions under consideration and so is very large.
In what follows of the paper, we propose an (approx-
imate) solution under the restriction that the total
number M of patients to be recruited at each step is
fixed and determined by the designer. (As we show in
the experiments, the choice of m can have a large im-
pact on the performance.) Our approach is greedy but
computationally tractable. The proposed algorithm,
RCT-KG, computes for each action a ∈ A the one-
stage reward that would be obtained by taking a, and
then selects the action with the maximum one-stage
reward
5 The RCT-KG Algorithm
Because solving the MDP is intractable, we offer a
tractable approximate solution. We focus on the set-
ting where the number of patients M in each cohort
is fixed: M = T/K. In this circumstance, what is
to be decided for each cohort (each step) is the num-
ber of patients to recruit in each subgroup and the
group-specific assignments of these patients (subject
to the constraint that the total number of patients
in each cohort is M). The action set is therefore
A =
{
u :
∑
x
∑
y u(x, y) =M
}
and the size of this ac-
tion set is |A| =
(
M+2X−1
2X−1
)
. The Rand-KG algorithm
computes an expected improvement in the terminal
value function by taking an action a ∈ A. The value
function at the terminal stage can be decomposed into
improvements in the value function, that is,
V K(SK) =
[
V K(SK)− V K(SK−1)
]
+ . . .+
[
V K(Sk+1)− V K(Sk)
]
+ V K(Sk)
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The Knowledge Gradient (KG) policy selects the ac-
tion that makes the largest improvement in the value
function at each instance, that is,
AKGk (s) = arg max
a∈A(s)
Ek
[
V K(P (s, a,W ))− V K(s)
]
= arg max
a∈A(s)
∫
w
V K(P (s, a, w))P(w|Sk) dw
Algorithm 1 Optimistic Action Computation
Input : Current state vector: s
Set optimal action u∗ = 0
for m = 1, . . . ,M do
for (x, y) ∈ X × Y do
Set s1 = P (s, u
∗, u∗ ⊙G(zmax))
Set s2 = P (s, u
∗, u∗ ⊙G(zmin))
Set u˜ = u∗ + 1(x,y)
Compute v1 = V
K(P (s, u˜, u˜ ⊙ G(zmax))) −
V K(s1)
Compute v2 = V
K(P (s, u˜, u˜ ⊙ G(zmin))) −
V K(s2)
Compute q(x, y) = max(v1, v2).
end for
Compute (x∗, y∗) = argmaxx,y q(x, y).
Update u∗ = u∗ + 1(x∗,y∗).
end for
Return ARCT−KG(s) = u∗.
However, computing the KG policy requires comput-
ing the posterior predictive distribution and posterior
expectation for each action in A. This is a computa-
tionally intractable procedure because the size of the
action space is on the order of O
(
M2X−1
)
. Hence
we propose the RCT-KG algorithm which computes
optimistic improvements in the value functions. Al-
gorithm 1 shows a tractable way of computing these
optimistic improvements. At each iteration m, the
procedure computes the maximum improvement in the
value function that can be obtained from an additional
sample from the pair (x, y) and increments that index
by 1. The complexity of computing ARCT−KG(s) is
only O(MX).
At each decision step k, the algorithm computes the
best action using the procedure in Algorithm 1 and
recruits and assigns patients accordingly. At the end
of the current decision step, the state vector is updated
based on the observed treatment outcomes. When the
patient budget is exhausted, our algorithm outputs (as
the estimated positive set) the set of subgroups with
clinically relevant improvements:
H+est = {x ∈ X : Px(s
K) ≥ 1− λ}
The pseudo-code for RCT-KG is given in Algorithm 2.
Algorithm 2 The RCT-KG Algorithm
Input : K, S0
for k = 1, . . . ,K do
Compute U∗k = A
RCT−KG(Sk) using Algorithm
1.
Recruit the patients based on U∗k , observe cumu-
lative treatment outcome W ∗k .
Update Sk+1 = Sk + (W ∗k , U
∗
k ).
end for
Compute Px(S
K) for all x.
Compute H+est = {x ∈ X : Px(S
K) ≥ 1− λ}.
Output : H+est.
6 Experiments
In all of our experiments, we use assume that the
outcome is either success or failure of the treatment
for that patient, and assume the outcomes follow a
Bernoulli distribution; we continue to assume that the
outcomes for each cohort of patients is observable be-
fore the succeeding cohort must be recruited and allo-
cated. (The clinical study in [He´bert et al.(1999)] pro-
vides a real-life example.) We assume there are identi-
fiable subgroups (e.g. distinguished as to male/female
and/or young/old). In each experimental setting we
generate 1000 independent experiments and report the
average over these 1000 experiments. We compare
the results of our algorithm with those of Uniform
Allocation (UA), aka repeated fair coin tossing, that
uniformly randomly recruits the patients from sub-
groups and uniformly assigns the patients to treat-
ment groups, and (where appropriate) with Thomp-
son Sampling (TS) [Agrawal and Goyal (2012)] that
draws the parameters of the outcomes for each action
and then selects the action with the best sample out-
comes and an adaptive randomization, and a variant of
DexFEM [Warner et al. (2015)], that shifts the treat-
ment allocation ratio towards treatments with higher
posterior variance. In the comparisons with TS and
DexFEM, we assume that the recruitment of patients
from subgroups is uniform and that it is only the allo-
cation of patients to treatment/control that depends
on previously observed outcomes.
For the first experiment we consider a setting with two
subgroups; for the remaining experiments, we consider
a setting with four subgroups.
6.1 Error Rates with Two Subgroups
We begin with a setting with 2 subgroups 0, 1. We
assume the true parameters for the subgroups are
θx,0 = 0.5 for x ∈ {0, 1}, θ1,1 = 0.7 and we vary
θ0,1 from 0.51 to 0.70. (Note that identifying the best
treatment is more challenging for subgroup 0 than for
subgroup 1.) We recruit 100 patients in each of 10 co-
horts – 1000 patients in total. Figure 2 compares the
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performance of our RCT-KG with UA in terms of error
rates; as can be seen, our algorithm outperforms UA
throughout the range of the parameter θ0,1, and the
improvement in performance is greatest in the middle
range of this parameter, when the difference between
treatment and control among the subgroups is great-
est. This improvement is achieved because our algo-
rithm recruits and samples more frequently from sub-
group 0, which represents the more challenging learn-
ing problem
6.2 Error Rates and Confidence Levels with
Four Subgroups
We now turn to a setting in which there are 4 sub-
groups 0,1,2,3. We take the parameters to be θx,0 =
0.5 for all x and θx,1 = 0.3, 0.45, 0.55, 0.7 for x =
0, 1, 2, 3. Note that there are two subgroups in which
the treatment action is ineffective and two subgroups
in which it is effective, and that identification is easier
in subgroups 0, 3 than in subgroups 1, 2. We examine
a number of aspects.
6.2.1 Confidence Levels Across Cohorts
In the first experiment in this setting, we recruit 100
patients in each of 10 cohorts, and compare the con-
fidence levels achieved for each cohort and for each
subgroup; the results for 4 horizons are shown in Ta-
ble 2. As can be seen, the RCT-KG, UA and DexFEM
algorithms achieve very similar confidence levels (prob-
ability of correctly identifying the actual label) for sub-
groups 0,3 at each of these time horizons, but RCT-KG
algorithm achieves significantly better confidence lev-
els for subgroups 1,2 – the subgroups for which iden-
tification is more difficult. RCT-KG achieves superior
confidence levels because it recruits more patients to
subgroups 1,2 and allocates patients in each subgroup
more informatively. To illustrate, we refer to Table 3,
which shows the total number of patients recruited to
each of the subgroups and the allocation of patients
to control and treatment within the subgroups. (Re-
member that we are reporting averages over 1000 ex-
periments.)
Algorithm/ SG 0 1 2 3
RCT-KG 98.79 82.92 83.56 98.78
DexFEM 98.94 79.28 79.25 99.00
UA 98.92 78.93 78.96 98.94
Table 2: Comparison of confidence levels on subgroups
6.2.2 Achieving a Prescribed Confidence
Level
In this experiment, we recruited 100 patients in each
cohort and continued recruiting patients until a pre-
scribed (average) confidence level β = 0.90, 0.95 was
SG 0 1 2 3
RCT-KG 81, 60 190, 181 186, 177 81, 54
DexFEM 137, 118 128, 127 128, 127 137, 118
UA 128, 127 127, 128 128, 127 127, 128
Table 3: Recruitment and allocation in each subgroup
# allocated to control, # allocated to treatment
achieved (i.e., until 1
X
∑
x∈X g(Px(S
k)) < 1 − β.) Ta-
ble 4 shows the number of cohorts necessary for each
algorithm to achieve the prescribed confidence level;
as can be seen, RCT-KG achieves the same confidence
level as UA and DexFEM using fewer cohorts of pa-
tients, which means that a RCT could be carried out
with fewer patients and completed in less time.
Algorithm β = 0.95 β = 0.90
RCT-KG 12.6 7.2
DexFEM 22.5 10.2
UA 22.9 10.7
Table 4: Comparison of length for a confidence level
6.2.3 Error Rates and Patient Budgets
In this experiment we recruited 100 patients in each co-
hort and computed the type-I, type-II and overall error
rates for various total patient budgets. As seen from
Figure 1, RCT-KG significantly outperformed the UA,
DexFEM and TS algorithms for all budgets. (TS did
especially poorly when the patient budget is large be-
cause TS aims to maximize the patient benefit, not the
learning performance, and so allocated more patients
to the treatment that has been found to be better at
each stage, which slows learning.)
6.2.4 Cohort Size
In this experiment, we compared the performance in
terms of total error of RCT-KG and UA when m pa-
tients were recruited in each cohort with a total budget
of 500 patients. As seen in Table 5, the error rate of UA
is independent of m because all patients are recruited
and allocated in the same way in every cohort, but the
error rate of RCT-KG is significantly smaller when m
is smaller because smaller cohorts provide more oppor-
tunities to learn.
m 25 50 100 250
RCT-KG 0.1245 0.1281 0.1292 0.1411
UA 0.1484 0.1484 0.1484 0.1484
Table 5: Total Errors for Different Cohort Sizes
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Figure 2: Total error rates for different parameter
6.3 Type 1 and Type 2 errors
Figure 6.3 illustrates the trade-off between type-I and
type-II errors for the RCT-KG algorithm (100 patients
in each of 10 cohorts.) Of course, as λ increases, the
type-I error decreases and the type-II error increases.
6.4 Informative Prior
In many circumstances, the clinicians controlling the
trial may have priors about the parameters of the out-
come distribution; of course these priors may be infor-
mative but not entirely correct. To illustrate the ef-
fect of having such informative priors, we conducted an
experiment in which informative priors were generated
by sampling 50 patients from each subgroup and treat-
ment group, but noting count these patients as part of
the total patient budget, which was either 500 or 1000.
As seen from Table 6, having an informative prior in-
creases the amount by which RCT-KG improves over
UA. Having an informative prior is useful because it
allows RCT-KG to make more informed decisions in
the earlier stages and in particular to focus more on
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Figure 3: Tradeoffs between Type-I and Type-II errors
subgroups for which the difference between the true
effectiveness of the treatment and control is smaller.
Budget 500 1000
Non-informative 0.1151 0.2813
Informative for sg 0,3 0.2000 0.3703
Informative for sg 1,2 0.1323 0.2878
Table 6: Improvement score for different budgets
7 Conclusion and Future Work
This paper makes three main contributions. (1) We
formalize the problem of recruiting and allocating pa-
tients in a RCT as a finite stage MDP. (2) We provide
a greedy computationally tractable algorithm RCT-
KG that provides an approximately optimal solution
to this problem. (3) We illustrate the effectiveness of
our algorithm in a collection of experiments using syn-
thetic datasets for which outcomes are drawn from a
Bernoulli distribution with unknown probabilities.
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The most important assumptions of this paper are
that patients can be recruited from subgroups that
are identified in advance and that the final outcomes
for patients in each cohort can be observed before pa-
tients in the next cohort are recruited from the various
subgroups and allocated to treatment/control. In fu-
ture work we will address both of these assumptions.
In particular, we will address the settings in which
subgroups are not identified in advance but must be
learned during the course of the trial, and the setting
in which only partial information about the outcomes
of earlier cohorts is known before patients in the next
cohort are recruited and allocated.
We have noted that this paper makes specific assump-
tions in order that our approach can be followed. We
should also add that actually constructing trials ac-
cording to the method suggested here will require con-
vincing both those who conduct the trials (e.g. phar-
maceutical companies) and those who assess the re-
sults of the trials (e.g. the regulatory agencies) that
the substantial improvements that are possible using
our method justify the changes to the way trials are
presently conducted.
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